Topping the victory over new FDA approval for Parkinson’s treatment

“In two to three years, the view could be beneficial,” Dr. Maurice Ferré, CEO of Veteran Isperial Compile Compoly, speaking “Globes” recently. Can’t stop useful? Let’s see. It is a company that of its existence increases $ 600 million, more than any other private-held private company in Israel, according to Startup Database at Ster Startup Nation Central. The money funded in the development of extraordinary technology, and the company has impressive income, but it continues to be heavy loss.

Ferré, which is in the CEO post in a decade, not sure it is possible to continue in such a way in today’s market situation.

“Up to a few years later, if money is easily available and the values ​​given to growing companies are high, good for a company to lose a lot of money,” he said. “Now, with an increase in interest rates, investors are difficult to allow the model, and drive companies to the demand, and we also target the direction.”

In his last raising funds last year, valuations to indulging only $ 515 million, as emerging from the financial company Elbit Medical, holding 2% of planting.

It begins to happen

Of course it’s best to be useful, but it can stop it? Ang pag-uyon nakadawat karong semanaha gikan sa pagkaon sa US ug tambal sa droga alang sa paggamit sa aparato sa dili makatarunganon alang sa usa ka bag-ong timailhan sa mga pasyente sa Parkinson sa istruktura sa Parkinson sa istruktura nga gitinguha ni Ferré nga magtinguha sa pagtukod. By focusing on ultrasound energy from many directions under the MRI guide, the product treats non-parkinson tremors, and in recent years various types of parkinson. “Competition technology is brainstorming with electrodes, a method that includes opening in the skull, and we will not take away our technology,” as obstacles to entering.

Company products are very expensive. The system itself can spend about $ 2 million, and treatments valued by thousands of dollars per patient. There is no patience or hospital to afford these treatments unless insurance companies cover them. So far, insurance coverage for the company’s products is relatively thin, but its new products are better than that respects than its predecessors.

“This piece of the puzzle is about to fall into place,” Ferré’s promise. “We recently demonstrated that, five years after treatment with our product of Initial Non-Parkinson’s tremors, 73% of patients are still in a better condition Than before the procedure. These insurance companies want to see, the patient is more active, less Sedentary, and less diabetic. “

In 2024, income closing $ 101 million from $ 83.5 million in 2023, and annual net loss from $ 100.6 million to $ 68.5 million. In the first quarter of 2025, the company posted a loss of $ 18 million, and at the end of the quarter has a cash of $ 148 million. “

Can you keep the company with no extra money?

Ferré: “No one knows, but our husband is our money to get enough of it for a long time, after we have reduced our burn rate.”

Published in Globes, Israel News in News – en.globes.co.il – On July 10, 2025.

© Copyright in Globes Publisher Itonut (1983) Ltd., 2025.